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INTRODUCTION 
Recurrent Aphthous Ulcer (RAU) or Recurrent Aphthous Stomatitis (RAS) is 
one of the common oral disease seen among the general population.
1 
According to 
Scully et al Stomatitis is defined as the inflammation of the oral cavity which occurs 
due to mechanical, chemical, thermal, bacterial, viral or radiation injury or as a 
secondary manifestation of any systemic disease. 
2, 3
 Hippocrates who is known as the 
Father of Medicine (460 to 370 BC) was the first person to use the term “aphthai”. It 
can occur in all ages, races and geographic regions without gender prevalence.
4
 
Factors including stress, genetics, nutritional deficiencies, diet, hormonal 
changes, immunological disorders are considered to be the etiology for RAS. 
2
 It may 
also be presented as widespread ulcerations in association with systemic conditions 
like Behcet’s syndrome, Reiter’s syndrome, Sweet syndrome, Crohn’s disease, Celiac 
disease, cyclic neutropenia etc. 
2,5
 Various other factors like cessation of smoking, 
oral trauma, food allergies can also predispose to aphthous stomatitis. 
2
  
 Due to its uncertain etiopathogenesis, these lesions are not clearly understood 
still and only symptomatic treatment can be given if clinically present. According to 
Ship (1996), there are no laboratory procedures which exist to confirm the diagnosis 
in case of RAS. Hence the diagnosis as well as treatment for this lesion is purely 
based on history and clinical criteria
. 6
 
 Majority of the patients presented with recurrent aphthous stomatitis are 
healthy without any systemic disease. Since definitive diagnosis is not possible with 
these patients, management of the lesion is to control the active disease locally to 
Introduction 
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reduce pain and maintain function, thus reducing the frequency and severity of 
remissions. 
7
  
Various treatment modalities are available which is useful in the management 
of recurrent aphthous stomatitis that includes topical anesthetic preparations such as 
benzocaine, Diclonine hydrochloride, Lidocaine with Diphenhydramine, topical as 
well as systemic corticosteroids, silver nitrate cauterization, antibiotics and laser 
therapy. Topical corticosteroids may cause side effects like cutaneous atrophy, oral 
candidiasis etc. 
8, 9
  
Since herbal medicines are gaining importance nowadays due to their 
decreased side effects, the present study was done by comparing the topical 
application of polyherbal formulation (HiOra SG gel) with triamcinolone acetonide 
0.1% (Oraways) in managing recurrent aphthous stomatitis. The ingredients of HiOra 
SG gel include Glycyrrhiza glabra, Jasminum grandiflorum, Azadirachta indica, 
Ocimum basilicum, Boerhaavia diffusa, Syzygium aromaticum and Triphala. A very 
few studies have been conducted to prove the efficacy of herbal medicines in 
recurrent aphthous stomatitis and therefore more studies are needed to substantiate its 
effects. Thus the purpose of this study was to compare the effectiveness of polyherbal 
formulation (HiOra SG gel) with Triamcinolone acetonide 0.1% in recurrent aphthous 
stomatitis. 
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AIM AND OBJECTIVES 
AIM: 
To compare the efficacy of HiOra SG gel with triamcinolone acetonide gel in 
recurrent aphthous stomatitis. 
OBJECTIVES: 
1. To assess ulcer severity on 1st, 5th and 10th day using ulcer severity score in 
individuals using HiOra SG gel. 
2. To assess ulcer severity on 1st, 5th and 10th day using ulcer severity score in 
individuals using triamcinolone acetonide gel. 
3. To compare the efficacy of HiOra SG gel and triamcinolone acetonide gel 
using ulcer severity scores.         
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REVIEW OF LITERATURE 
DEFINITION  
Graykowski et al in 1966 defined Recurrent Aphthous Ulcer (RAU) as an 
inflammatory condition of unknown etiology characterized by painful, recurrent 
(Single or multiple) ulcerations of the oral mucosa. It is the most common oral 
mucosal pathoses known to human beings. 
10
  
According to Edgar et al (2017) Recurrent aphthous stomatitis is defined as 
the most common ailment affecting the oral cavity, with recurrent disruption of the 
oral mucosa due to recurrent inflammatory process resulting in painful ulcers.
11
 
EPIDEMIOLOGY  
Almost 20% of the general population is affected by RAS, but when specific 
socioeconomic groups are studied, the incidence ranges from 5% to 50%. Among 
them, the higher socioeconomic status groups are mostly affected by RAU.
  2, 12
  
 Field et al in 1992 studied about the pattern of recurrent aphthous stomatitis in 
children and found that the peak age of onset is between 10-19 years of age. 
13
 In 
1985 Axell T et al did a study in 20,333 individuals to find the prevalence of RAS in 
urban, suburban and rural regions of Sweden and prevalence rate was 17.7%. A slight 
female predominance was also present. The average number of recurrences per year 
was about 2-4 with an average healing time of about 5-8 days. 
14
 
  Ship et al in 1960 studied about the prevalence among medical and dental 
students and had a high prevalence rate of about 54.4% and 66.2% respectively. 
15
 In 
2000, Reichert et al found out the prevalence in 655 German individuals based on 
patient history was 18.2%. 
16
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Patil et al in 2014 did a study to determine the prevalence of recurrent 
aphthous ulcerations in Indian Population and the results indicated a prevalence rate 
of 21.7%. The most commonly affected were females ( 56.3%) and occurrence of 
disease in males was less (43.7%). 
17
 
PREDISPOSING FACTORS 
According to Scully et al few predisposing factors for RAS include: 
2
 
a) Stress 
b) Trauma 
c) Haematinic deficiency (deficiencies of iron, folic acid (folate) or vitamin B12) 
d) Sodium lauryl sulphate (SLS), a detergent in some oral healthcare products 
e) Cessation of smoking 
f) Gastrointestinal disorders particularly celiac disease (gluten-sensitive 
enteropathy) and Crohn’s disease in about 3% of patients 
g) Endocrine factors especially low levels of progesterone during luteal phase of 
menstrual cycle 
h) Immune deficiency 
i) Food allergies rarely 
ETIOPATHOGENESIS 
In about one third of the patients with RAS, genetic predisposition along with 
positive family history is present. 
2
 Lehner et al in 1978 reported that at least two 
types of damaging immune mechanisms have been identified; cell‐ mediated and 
immune complex induced reactions which may be responsible for the pathogenesis of 
RAS. 
18
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Mills et al in 1980 found that the predominant cells in the aphthae regions are 
leukocytes, which are seen infiltrated due to the triggering of inflammatory cascade 
by the predisposing factors. In the initial phase of the disease before ulcer formation, 
monocytes and lymphocytes (mainly of the T type) together with single mast and 
plasma cells accumulate under the basal cell layer. The polymorphonuclear 
leukocytes dominate in the center of the ulcer; while on the border of the lesion 
abundant mononuclear cell inﬁltration can be seen in the more advanced stage. 16, 17  
In 1985, Savage et al reviewed on immune dysregulation associated with 
RAS. He found that T4 cells predominate in the preulcerative and healing phase 
where as T8 lymphocytes were increased in number in case of the ulcerative phase of 
RAS. 
20
  The expression of Class I and Class II Major Histocompatibility Complex 
antigens during all the ulcer stages in RAS which is directed against the epithelium, 
thereby attacking and killing the cells of epithelium. 
21
 
  A secondary pathogenic mechanism was explained by Schroeder et al in 1984 
and he suggested that epithelium is disrupted due to the binding of various 
immunoglobulins and complement to the epithelium and to vessel walls. 
7, 20
 
 Wray et al in 1991 reported that release of Tumor Necrosis Factor (TNF) and 
increased cohesion of neutrophils may help in the maintenance of the ulcerative stage 
of RAS. 
7, 21
 Elevated immunoglobulins Ig G, A, D and E also have been reported. 
7, 24
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CLINICAL FEATURES 
Stanley et al in 1972 divided the clinical features of aphthous stomatitis into 
four stages namely Premonitory stage, Pre ulcerative stage, Ulcerative stage and 
Healing stage.
25
 
Premonitory stage- The duration of this stage is the first 24 hours and the 
patients will experience burning or tingling sensation. 
Pre ulcerative stage- The occurrence of this stage happens during the first 18-
72 hours and there will be initial development of ulcer formation with the presence of 
macules or papules associated with erythematous halo. During this stage, there will be 
increase in the intensity of pain experienced by the patients. 
Ulcerative stage- The third stage or the ulcerative stage may prolong from a 
few days to two weeks. The macules or papules may turn into ulcer at this stage 
which is covered by a yellowish white pseudomembraneous slough. The intensity of 
pain may decrease during this period. 
Healing stage- The duration of this stage may exist from 4 days and may 
extend up to 35 days. At this stage, there will not be any pain reported by the patients 
where we can appreciate wound healing and there will be formation of epithelium. 
Thus the healing occurs either with scar formation or without scar formation. 
25
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According to Cooke et al (1969) and William et al (1992), recurrent aphthous 
stomatitis can be classified based on the patient history and clinical aspects into three 
categories. 
12, 23
 
1. Minor aphthous ulcers 
2. Major aphthous ulcers 
3. Herpetiform ulcers 
Minor Aphthous Ulcers (MiAU) 
 In 1888, Mikulicz and Kummel described first about Minor Aphthous 
ulcerations. MiAU occurs as recurrent crops of 1-5 punched out ulcers which mostly 
affects the non keratinized mucosa of the oral cavity that includes lips, buccal 
mucosa, and Mucobuccal and labiobuccal sulci. Slight female predilection is found in 
case of MiAU. Age of onset is 10-19 years and the size of the lesion may vary from 
1mm up to 10mm approximately. Roger (1977) has reported about 8% of cases which 
heals with scarring. 
25
  Within 1-2 weeks, the ulcerations can heal. 
27
 
Major Aphthous Ulcers (MjAU) 
 In 1911 Sutton described about major aphthous ulcer and he used the term 
‘Periadenitis mucosa necrotica recurrens’. 24, 25  Later Cooke and Lehner in 1968 
introduce the term Major aphthous ulcers. 
24,  26, 27
. These type of ulcerations appear as 
recurrent large, chronic, and usually solitary ulcers that most commonly affects the 
keratinized or non keratinized mucosa of oral cavity like lips, cheeks, tongue, palate, 
pharynx etc,. Characteristic female: male ratio is about 0.8: 1. Age of onset is about 
10-19 years and the size of the ulcers is usually >10mm. These ulcers starts as nodules 
and deep tissues will be destroyed finally resulting in scarring. About 64% of ulcers 
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heal with scarring. 
18, 25
  Up to 6 weeks, the ulcerative lesions may exist within the 
oral cavity. 
Herpetiform Ulcers: (HU) 
 In 1960 Cooke discussed about the third type of aphthous ulcer as 
‘Herpetiform” ulcers as it resembles the ulcerations due to viral infections. They 
appear as recurrent, multiple, shallow, pinpoint ulcers which may attack any part of 
the oral mucosa. MjAU and HU are relatively rare when compared to MiAU. Female: 
male ratio reported by Lehner was 2.6:1 and the age of onset is 20-29 years. The size 
of the ulcers is 1-2 mm but the number of ulcers which appear during one crop may 
vary from 10-100 approximately. About 32% ulcers heal with scarring. 
24, 26, 28
  
MANAGEMENT 
The factors on which the management strategy depends are disease severity in 
terms of pain, duration, the patient’s medical history, the frequency of recurrences and 
the patient’s ability to tolerate the medication given.31 Treatment for Recurrent 
aphthous stomatitis can be of either local therapy or systemic therapy and other 
physical treatment modalities which include low energy laser ablation, cauterization, 
surgical removal etc.,.
25, 29
 
A treatment ladder has been suggested by Ship J A et al in 2000, for the 
management of RAS which consist of Primary line, secondary line and tertiary line of 
management. 
32
 
Primary line of management includes: 
 Use of various topical creams/rinses 
 Treatment of nutritional and haematological deficiencies 
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 Avoidance of allergy causing foods 
 Treatment of underlying systemic diseases 
Secondary line of management includes: 
 Indicated for those patients whose symptoms are not relieved by primary line 
of treatment.   
 Both in seropositive and negative cases of HIV, Prednisone have been 
prescribed at a dosage of 1.0 mg/kg /day as a single dose that is to be tapered 
within 1-2 weeks. 
Tertiary line of management includes: 
 In cases where seropositivity for HIV, Thalidomide has been prescribed 
 Levamisole 150mg/Kg has also been recommended 
Topical Therapy 
Porter et al in 2000, Greenberg and Pinto et al in 2003 and Puri et al in 2015 
has reviewed on various topical therapies administered for recurrent aphthous 
stomatitis. The different topical therapies include topical anesthetics, antiseptics and 
anti- inflammatory agents, antimicrobials, corticosteroids and immunomodulatory 
agents. 
25, 29, 31
 
1. Topical Anesthetics 
In 2011 Descroix V et al did a randomized, double-blind, placebo-controlled, 
parallel group single dose study to determine the efficacy 0f 1% Lidocaine in the 
treatment of pain associated with minor oral aphthous ulcer and found that the 
application of 1% Lidocaine cream led to the pain reduction when compared to 
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placebo. 
32, 33
  He also reviewed that a combination of Tetracaine 0.5% and 
Polidocanol 0.1% pump spray and mouth wash containing Benzocaine and 
Cetylpyridinium chloride can also be used to alleviate the pain associated with RAS. 
In 2018 a clinical study done by Gasparini et al to evaluate the efficacy of 
topical application of Ropivacaine 100mg in 10 ml showed that it  had a rapid and 
long-lasting effect on the pain symptoms of RAS through which the quality of life in 
patients suffering from aphthae has been enhanced. 
36
 
2. Antiseptics and anti-inflammatory agents 
In 1974 by Addy et al Randomized controlled clinical trials (RCT) have been 
done for the management of RAS using chlorhexidine mouth rinses and results 
showed marked reduction in duration of RAS and also increase in Ulcer-free periods. 
36, 37
 
It was Kjarheim et al in 1995 who reported about the anti-inflammatory and 
antiseptic properties of Triclosan. In 1996 Skaare AB et al reported that Triclosan 
mouth rinse can be used in the treatment of RAS and it has the ability to reduce the 
number of ulcers, relieves pain and also reduces the duration of ulcerative phase 
which helps in a faster healing of the ulcers. 
39, 40
  
Lee and Jung et al in 2008 did a RCT to determine the efficacy of topical 0.2% 
Hyaluronic acid gel in recurrent oral aphthous ulcers and Behcet’s disease and found 
that 0.2% Hyaluronic acid gel can be used as an effective topical agent in recurrent 
oral ulcers. 
41
 
Therapeutic effects of  Ibuprofen, Diphenhydramine and Aluminum 
magnesium simethicone (AlMgS) syrup on reducing oral aphthous ulcer pain were 
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studied using a RCT in 2014 by Katayoun Borhan-Mojabi et al and concluded that  no 
significant difference was detected between the two groups regarding the duration of 
pain or burning sensation (P=0.57). 
42
 
Another RCT was done by Darshan et al in 2014 to determine the efficacy of 
amlexanox 5% topically 4 times daily in RAS which was compared with 
Benzalkonium chloride 0.01%, Choline salicylate 8.7% and Lidocaine hydrochloride 
2%. This study showed that Amlexanox group had significant reduction in number, 
size; erythema, pain and frequency of ulcers during follow up. 
43
 
In 2014 Gül Soylu Özler et al did a clinical trial to compare the efficacy of 
Sucralfate suspension with chlorhexidine oral rinse. The results showed that 
significant lowering in pain scores and increase in reepithelialization of the oral 
ulcerations was seen in Sucralfate group when compared to chlorhexidine group. 
44
 
3. Topical Corticosteroids 
According to Guallar et al, topical corticosteroids are the most commonly used 
drug for the management of immunological oral mucosal diseases. 
45
 
Al Namah et al in 2009 compared the efficacy of dexamethasone 0.1% topical 
gel with triamcinolone acetonide 0.1% in treating RAS and concluded that 
dexamethasone had a quicker healing rate when compared to triamcinolone acetonide 
with a significant P value < 0.001. 
46
 
Fani et al in 2012 compared the efficacy of Triamcinolone acetonide 0.1% oral 
paste with Phenytoin syrup used as mouth wash which was applied thrice daily for 4-5 
minutes for about 1 week. The results showed that TA gel had a significantly higher 
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response rate (86.7%) when compared to Phenytoin syrup (53.3%) (P value=0.01) 
32, 
44
 
Koray M et al conducted a study in 2016 to evaluate the efficacy of topical 
Hyaluronic acid gel and compared with triamcinolone acetonide (TA) in the treatment 
and pain control of RAS. The pain symptoms were reduced significantly in 
Hyaluronic acid group with a p value <0.05. 
48
 
4. Topical Antibiotics 
In 1994 Hayrinen et al did a study to find out the efficacy of Chlortetracycline 
in patients with RAS by topical rinsing of the medication. The results showed that 
irritations associated with the lesions were alleviated. 
37, 49
 
Skulason et al in 2009 did a randomized; double- blind placebo- controlled 
clinical assessment using the saliva of recurrent aphthous stomatitis patients after 
treatment with low-dose Doxycycline in a hydrogel and found that due to inhibition of 
matrix metalloproteinase enzymes, there was reduction in pain for the patients with 
Aphthous ulcers. 
50
 
Systemic medications 
In severe RAS cases systemic medications which include corticosteroids, anti 
TNF α agents like Pentoxifylline, Thalidomide, Adalimumab, Colchicine, 
Levamisole, Other immunomodulatory agents etc., can be administered. 
37
. 
In 2005, Justin Vujevich et al treated a severe, recalcitrant, major aphthous 
stomatitis case with Adalimumab, a recombinant, fully humanized IgG1 monoclonal 
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antibody administered as 40mg injection subcutaneously every other week for 4 
months and there were no recurrences at the end of 4
th
 month. 
51
 
Thornhill et al in 2007 did a 60-day, randomized, double-blind, placebo 
controlled trial for the treatment of RAS where  400mg of Pentoxifylline was given 
thrice daily and followed by  a 60-day no treatment and he concluded that patients 
taking Pentoxifylline had less pain with smaller and fewer ulcers compared with 
baseline and more ulcer free periods when compared to placebo. 
52
 
Lynde et al in 2009 did a clinical trial using colchicine 0.6mg once daily and 
dapsone 125-150 mg daily and results showed that colchicine can be used as a first 
line corticosteroid sparing therapy and dapsone as second line systemic management 
for complex aphthosis. 
53
 
In 2010 Muriel et al did a multicentre cohort study to determine the efficacy of 
Thalidomide which was administered 50 mg/day for Severe Recurrent Aphthous 
Stomatitis and found that low dose maintenance regimen is effective in such cases. 
54
 
In 2014 Parvathi Devi et al did a study to determine the efficacy of 
Rebamipide and Levamisole in the management of recurrent aphthous stomatitis in 
100 patients. The overall results showed that Rebamipide had a same efficacy with 
that of Levamisole. 
55
 
ADVERSE EFFECTS OF TOPICAL CORTICOSTEROIDS 
 In 2010 Gonzales-Moles et al mentioned the adverse effects of topical 
corticosteroids in a review article which states that there are local as well as systemic 
side effects with the usage of topical corticosteroids. One of the most common local 
complications occurs secondary to the use of topical corticosteroids is Oral 
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candidiasis. Burning mouth, hypogeusia, Oral hairy leukoplakia and hypersensitive 
reactions to the drug were also mentioned as the local side effects. 
56
 
 Management with high potency corticosteroids like Clobetasol propionate 
when used with maximum dosage of three rinses per day for more than 10 days of 
treatment duration can lead to systemic absorption of the drug which can cause 
suppression of the hypothalamic pituitary adrenal axis and can result in rare 
complications like moon face, hirsutism and capillary fragility. 
56
 
NATURAL TREATMENT FOR RECURRENT APHTHOUS ULCERS 
In 2017 Fetrat et al did a systematic review about the natural topical treatment 
of RAS and described about various natural ingredients like Licorice, Curcumin gel, 
Ginger extract, Aloe Vera, Honey, and Guava leaves mouthwash etc., which can be 
used in the treatment of recurrent oral ulcers. The results showed that topical 
management using natural products showed beneficial effects on oral ulcers without 
any side effects. 
57
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MATERIALS AND METHODS 
SOURCE OF DATA 
 The present study was a randomized controlled clinical trial to compare the 
effectiveness of HiOra SG gel with Triamcinolone acetonide gel in recurrent aphthous 
stomatitis. The study was conducted at Vivekanandha Dental College for Women, 
Elayampalayam, Tiruchengode Tk., Namakkal District, Tamil Nadu.   
ETHICAL CLEARANCE   
A detailed protocol about the aim and procedures of the present research was 
submitted to the Institution Ethical Committee, Vivekanandha Dental College for 
Women. The study was carried out only after obtaining ethical clearance.   
SAMPLE SIZE 
 The study was on 60 patients from the outpatient department section of 
Vivekananda dental college for women, Tiruchengode. The sample size was estimated 
and the study consisted of 2 groups. 
a) Group I (HiOra SG gel Group)           –  30 subjects  
b) Group II (Triamcinolone acetonide group) –  30 subjects 
The required sample size with 90% power was estimated as 30 per group with 
a total of 60 subjects. The details of the research were explained to all the participants 
and written consent was obtained from all of them. 
INCLUSION CRITERIA 
1. Individuals of either gender, aged 18 years and above. 
  2. Individuals Diagnosed with Recurrent aphthous stomatitis 
                                                                                       Materials and Methods 
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DIAGNOSTIC CRITERIA 
 According to Rogers, the diagnosis of RAS is done clinically by the following 
criteria 
25
: 
a) Round or ovoid shaped ulcerations with yellowish necrotic bases surrounded by 
erythematous halo 
b) Ulcers with size less than 1cm are considered as Minor recurrent ulcers 
c) Ulcers with size more than 1cm are considered as Major recurrent aphthous 
ulcers 
EXCLUSION CRITERIA 
Individuals with the following criteria were excluded 
1. Allergic to any topical pharmaceutical products 
2. With any other systemic diseases 
3. With chronic ulcerative conditions 
4. Under long term medication 
5. Pregnant and lactating women 
MATERIALS USED 
Examination of subject was done using the following instruments. 
1. Dental chair with good lighting attachment was used   
2. Disposable gloves and mask   
3. Stainless steel kidney tray  
                                                                                       Materials and Methods 
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4. Disposable paper cups with water   
5. Sterilized diagnostic instruments  
i. Mouth mirror   
ii. Straight probe 
iii. Explorer  
iv. Tweezers   
v. Cotton rolls 
vi. William’s periodontal probe   
 
 
 
 
 
 
Figure1: Materials used for the Study 
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19 
 
 
MEDICATIONS GIVEN FOR THE PATIENT: 
 HiOra SG gel: - HiOra-SG is a polyherbal dental formulation recommended 
for the management of mouth ulcers, teething pain, and denture irritation. It 
has ulcer-healing action, which helps promote healing of mouth ulcers and 
prevents recurrence. It also acts against oral pathogens that damages the oral 
mucosa, and relieves the pain and inflammation associated with ulcers. 
COMPOSITION 
           Each gram of HiOra-SG gel contains: 
Jati (Jasminum grandiflorum) 20 mg 
Yashti (Glycirrhiza glabra) 8 mg 
Triphala 6 mg 
Punarnava (Borrhevia diffusa) 6 mg 
Lavanga (Syzygium aromaticum) 5 mg 
Vanatulasi (Ocimum basilicum) 3.3 mg 
Nimba (Azadiracta indica) 1.7 mg 
 
 Triamcinolone acetonide (0.1% w/v) 
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METHODOLOGY 
COLLECTION OF DATA 
 The patients were included in the study based on the diagnostic and inclusion 
criteria. Examination is done using diagnostic instruments like mouth mirror, straight 
probe, explorer, tweezers and William’s periodontal probe. The demographic details, 
detailed medical history and dental history is taken and documented in the Patient 
proforma. Patient proforma is enclosed in the annexure.  
The clinical findings of the patient were recorded on 1
st
, 5
th
 and 10
th
 day after 
examination in the specialized proforma for this study by the first observer. The 
medications given were wrapped to look similar and were given to the patients by a 
second observer for double blinding. HiOra SG gel was coded as DRUG-A and 
Triamcinolone acetonide gel was coded as DRUG-B. Once the study was over the 
drug details were decoded to the first observer and investigator to prepare the master 
chart. 
 
Figure 2: Medications used for the study 
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METHOD OF APPLICATION OF MEDICATION 
Individuals were advised to take HiOra SG gel or 0.1% triamcinolone 
acetonide gel at the tip of the index finger and apply it over mouth ulcers 4-5 times 
daily after meals for a period of 10 days. The clinical findings were evaluated as per 
Ulcer Severity Score and were recorded in patient proforma. No other topical or 
systemic medications were administered during the period of the study. Skin 
examination was also done locally during each visit. Patients were permitted to 
withdraw from the study at any point when they needed.  
ULCER SEVERITY SCORE 
According to Tappuni et al ulcer severity score is calculated as follows 
64
: 
CRITERIA ULCER SEVERITY SCORE 
NUMBER OF ULCERS 
Score= average number of ulcers in a crop, max score= 10 
SITE OF THE ULCERS 
Score= total of sites affected 
Score=1 for each non keratinized site 
Score= 2 for each keratinized site 
SIZE OF THE ULCERS Average size in mm, max score=10 
PAIN INTENSITY 
On numerical scale of 0-10 with 0 for no pain and 10 for 
excruciating ulcer 
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PAIN DURATION 
1
ST
 FOLLOW UP 2
ND
 FOLLOW UP 
 
 
 
Pain duration: Score = Total No of days of pain reported by the patient on 1
st
 
follow up and 2
nd
 follow up , Pain duration score= 1 for each day; with Max Score=5  
FOLLOW UP 
 The severity of the ulcers was examined on 5
th
 and 10
th
 days and assessments 
were documented on the patient proforma. Also the pain duration during each follow 
up is also recorded. 
 
 
 
 
 
 
Figure 3: Recurrent Aphthous Ulcer involving lower labial mucosa on Day 1 
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Figure 4: Recurrent aphthous ulcer involving lower labial mucosa on 
first follow up (Day 5) 
Figure 5: Healed aphthous ulcer involving lower labial mucosa on Second 
follow up (Day 10) 
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Figure 6: Recurrent aphthous ulcer involving lower labial mucosa on 
day 1 
Figure 7: Recurrent aphthous ulcer involving lower labial mucosa on 
day 5 
                                                                                       Materials and Methods 
25 
 
 
 
Figure 8: Healed Ulcer site involving lower labial mucosa on Day 10 
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STATISTICAL ANALYSIS 
Data collected was collected and arranged in Microsoft Excel spreadsheet and 
a master chart was prepared. The data was subdivided according to the study groups. 
The statistical analysis was carried out using Statistical Package for Social Sciences 
software (SPSS version 16).  Sample size estimation was done using the formula    
n=  t² x p(1-p) 
  m² 
     n= required sample size 
t= confidence interval of 95% 
p= expected frequency of factor under study 
m= Margin of error of 5%  
Quantitative variables are compared using Student t test and multiple 
comparisons were done using ANOVA with Posthoc test. Gender distribution was 
compared between the groups using Chi square test.  
Null Hypothesis – There is no significant difference between the effectiveness of 
HiOra SG gel and Triamcinolone acetonide gel in the management of recurrent 
aphthous stomatitis. 
The minimum level of significance was fixed at 0.05. p value ≤ 0.05 indicates 
strong evidence against the null hypothesis. 
 
RESULTS
Results  
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RESULTS 
TABLE 1: AGE DISTRIBUTION 
 
 
 
 
n = number of subjects 
Group I – 4(13%) were less than 20 years, 15(50%) were between 21-30 
years, 9(30%) were between 31-40 years, 2(7%) were between 41-50 years and none 
of them were there in 51-60 years. 
Group II – 7(23%) were less than 20 years, 16(53%) were between 21-30 
years, 4(13%) were between 31-40 years, none of them between 41-50 years and 3 
(10%) were between 51-60 years of age.  
The distribution of patients with RAS in the present study was more within the 
age range of 21- 30 years in both study groups.  
 
 
STUDY GROUP 
 
AGE GROUP HIORA n (%) TRIAM TOTAL 
<20 4(13%) 7(23%) 11 
21 - 30 15(50%) 16(53%) 31 
31 - 40 9(30%) 4(13%) 13 
41 - 50 2(7%) 0 2 
51 - 60 0 3(10%) 3 
Total 30 30 60 
Results  
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TABLE 2: GENDER DISTRIBUTION 
GENDER DISTRIBUTION 
 
STUDY GROUP 
GENDER HIORA TRIAM 
MALE 5(17%) 10(33%) 
FEMALE 25(83%) 20(67%) 
 
Group I – 5 (17%) were males and 25 (83%) were females. 
Group II – 10(33%) were males and 20 (67%) were females. 
The gender distribution in the two groups showed increased number of 
females with RAS. But p value was >0.05 which showed that distribution of aphthous 
ulcer among males and females were not statistically significant. 
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TABLE 3: COMPARISON BETWEEN PAIN SCORES ON 1
ST
, 5
TH
 AND 10
TH
 
DAYS IN HIORA GROUP 
    
 
95% CI for 
Mean 
   
PERIOD Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum P-value 
DAY1 6.63 1.752 0.32 5.98 7.29 3 10 
 
DAY5 2.77 1.977 0.361 2.03 3.5 0 7 p <0.001* 
DAY10 0.57 1.04 0.19 0.18 0.96 0 3 
 
Total 3.32 2.997 0.316 2.69 3.95 0 10 
 
SD = Standard Deviation             * = statistically significant               p-value = <0.001 
 
The mean pain scores in HiOra group were given as mean ± SD. On day 1 
mean VAS score was 6.63± 1.752 and on day 5 and day 10 the VAS pain scores 
reduced to 2.77± 1.977 and 0.57± 1.04 respectively.  Thus the total mean pain score 
was 3.32± 2.997. ANOVA test was used to compare the Pain scores. The p value was 
<0.001 which showed a significant reduction in the pain intensity. 
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TABLE 4: COMPARISON BETWEEN PAIN SCORES ON 1
ST
, 5
TH
 AND 10
TH
 
DAYS IN TRIAMCINOLONE ACETONIDE GROUP 
    
 
95% CI for Mean 
 
   
PERIOD Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY1 6.6 1.993 0.364 5.86 7.34 3 10 
 
DAY5 2.7 1.643 0.3 2.09 3.31 0 7 p <0.001* 
DAY10 0.37 0.928 0.169 0.02 0.71 0 4 
 
Total 3.22 3.023 0.319 2.59 3.86 0 10 
 
SD = Standard Deviation             * = statistically significant              p-value = <0.001 
 
The mean pain scores in Triamcinolone group was given as mean + or – SD. 
On day 1 mean VAS score was 6.6± 1.993 and on day 5 and day 10 the VAS pain 
scores reduced to 2.7±1.643 and 0.37± 0.928 respectively. Thus the total mean VAS 
score calculated was 3.22±3.023. And the p value was <0.001 which showed a 
significant decrease in the pain intensity during the follow up period. 
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TABLE 5: COMPARISON BETWEEN TOTAL ULCER SEVERITY SCORES 
ON DAY1, DAY 5 AND DAY 10 IN HIORA GROUP 
 
    
95% CI for 
Mean 
 
   
PERIOD Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY1 16.43 11.855 2.164 12.01 20.86 6 68 
 
DAY5 9.23 9.946 1.816 5.52 12.95 0 54 
p 
<0.001* 
DAY10 2.43 3.342 0.61 1.19 3.68 0 10 
 
Total 9.37 10.71 1.129 7.12 11.61 0 68 
 
SD = Standard Deviation             * = statistically significant              p-value = <0.001 
 
The mean total ulcer severity scores in HiOra group on day 1, day 5 and day 
10 were compared in table 5. The result showed that the mean Total USS on day 1 
was 16.43±11.855 which reduced to 9.23±9.946 and 2.43±3.342 on day 5 and day 10 
respectively. The p value was found to be < 0. 001 and this showed that the Total USS 
was statistically significant in HiOra group. 
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TABLE 6: COMPARISON BETWEEN TOTAL ULCER SEVERITY SCORES 
ON DAY1, DAY 5 AND DAY 10 IN TRIAMCINOLONE ACETONIDE GROUP 
 
    
95% CI for Mean 
   
PERIOD Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY1 13.97 5.249 0.958 12.01 15.93 7 33 
 
DAY5 7 4.871 0.889 5.18 8.82 0 26 p <0.001* 
DAY10 1.97 4.013 0.745 0.44 3.49 0 18 
 
Total 7.71 6.813 0.722 6.27 9.14 0 33 
 
SD = Standard Deviation             * = statistically significant              p-value = <0.001 
 
Table 6 shows the total Ulcer severity scores on day 1, day5 and day 10 in 
triamcinolone group. The mean± SD of total USS on the first day was 13.97+/- 5.249 
which decreased to 7±4.871 and 1.97±4.013 on day 5 and day 7 respectively. The p 
value obtained was <0.001 and this showed that the mean total ulcer severity scores 
had a statistically significant difference. 
 
 
 
Results  
 
33 
 
 
TABLE 7: COMPARISON OF PAIN SCORES BETWEEN THE TWO STUDY 
GROUPS 
 
     
 
95% CI for 
Mean 
   
  
Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY 
1 
HIORA 6.63 1.752 0.32 5.98 7.29 3 10 
 
 
TRIAM 6.6 1.993 0.364 5.86 7.34 3 10 0.945 
DAY 
5 
HIORA 2.77 1.977 0.361 2.03 3.5 0 7 
 
 
TRIAM 2.7 1.643 0.3 2.09 3.31 0 7 0.888 
DAY 
10 
HIORA 0.57 1.04 0.19 0.18 0.96 0 3 
 
 
TRIAM 0.37 0.928 0.169 0.02 0.71 0 4 0.435 
SD = Standard Deviation              
 
Table 7 shows the comparison of pain scores between the two study groups on 
day 1, day 5 and day10. The p value on day 1 was 0.945 and on day 5 was 0.888 and 
on day 10 it was 0.435. As the p values were >0.05, the comparison of pain scores 
between the study groups were not statistically significant. This showed that there was 
no significant difference between the two groups in alleviating the pain caused by 
RAS. 
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TABLE 8: COMPARISON OF TOTAL ULCER SEVERITY SCORES 
BETWEEN THE STUDY GROUPS 
 
  
Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY 
1 
HIORA 16.43 11.855 2.164 12.01 20.86 6 68 
 
 
TRIAM 13.97 5.249 0.958 12.01 15.93 7 33 0.302 
DAY 
5 
HIORA 9.23 9.946 1.816 5.52 12.95 0 54 
 
 
TRIAM 7 4.871 0.889 5.18 8.82 0 26 0.274 
DAY 
10 
HIORA 2.43 3.342 0.61 1.19 3.68 0 10 
 
 
TRIAM 1.97 4.013 0.745 0.44 3.49 0 18 0.628 
SD = Standard Deviation              
Table 8 shows comparison between Total Ulcer Severity Scores on day 1, day 
5 and day 10 among the study groups. On day 1 the p value was 0.302 and on day 5 p 
value was 0.274 and on day 10 p value was 0.628.  
p values were >0.05 and showed that Ulcer Severity Scores between the study 
groups were not statistically significant. Thus the results demonstrated that there was 
no significant difference in the USS between the two groups after the treatment.  
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TABLE 9: COMPARISON OF PAIN DURATION AFTER USING HIORA ON 
DAY 5 AND DAY 10 
 
    
 
95% CI for Mean    
PERIOD Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY5 4.33 0.844 0.154 4.02 4.65 2 5 
 
DAY10 1.57 1.654 0.302 0.95 2.18 0 5 <0.001* 
Total 2.95 1.908 0.246 2.46 3.44 0 5 
 
SD = Standard Deviation             * = statistically significant              p-value = <0.001 
 
The mean pain duration was 4.33±0.844 on day 5 and 1.57±1.654 on day 10 
after using HiOra gel. p value obtained was <0.001 which demonstrated that there was 
significant difference in the pain duration. 
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TABLE 10: COMPARISON OF PAIN DURATION AFTER USING 
TRIAMCINOLONE ACETONIDE ON DAY 5 AND DAY 10 
 
PERIOD Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum p-value 
DAY5 4.2 0.997 0.182 3.83 4.57 2 5 
 
DAY10 1.34 1.696 0.315 0.7 1.99 0 5 <0.001* 
Total 2.8 1.989 0.259 2.28 3.32 0 5 
 
SD = Standard Deviation             * = statistically significant             p-value = <0.001 
 
The mean pain duration obtained after using triamcinolone on day 5 and day 
10 were 4.2±0.997 and 1.34±1.696 respectively. p value was <0.001 which showed 
that there was statistically significant difference in the pain duration after using 
triamcinolone during follow up. 
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TABLE 11: COMPARISON OF PAIN DURATION BETWEEN HIORA 
GROUP AND TRIAMCINOLONE ACETONIDE GROUP 
 
  
Mean SD 
Std. 
Error 
Lower 
Bound 
Upper 
Bound 
Minimum Maximum 
p-
value 
DAY 
5 
HIORA 4.33 0.844 0.154 4.02 4.65 2 5 
 
 
TRIAM 4.2 0.997 0.182 3.83 4.57 2 5 0.578 
DAY 
10 
HIORA 1.57 1.654 0.302 0.95 2.18 0 5 
 
 
TRIAM 1.3 1.685 0.308 0.67 1.93 0 5 0.539 
SD = Standard Deviation              
 
Table 11 shows the comparison of pain duration between HiOra group and 
triamcinolone group on day 5 and day 10. p value of day 5 was 0.578 and day 10 was 
0.539 which demonstrated that the pain duration after using both HiOra gel and 
triamcinolone gel was found to be statistically insignificant as the p value was > 0.05. 
Hence it showed that there was no significant difference in pain duration between 
both the study groups. 
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GRAPH 1: AGE DISTRIBUTION 
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GRAPH 2: GENDER DISTRIBUTION 
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GRAPH 3: BOX PLOT SHOWING COMPARISON OF PAIN SCORES 
BETWEEN HIORA GROUP AND TRIAMCINOLONE ACETONIDE GROUP 
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GRAPH4: BOX PLOT SHOWING COMPARISON OF TOTAL ULCER 
SEVERITY SCORES BETWEEN HIORA GROUP AND TRIAMCINOLONE 
ACETONIDE GROUP 
 
 
 
 
 
 
 
 
Results  
 
42 
 
GRAPH 5: BOX PLOT SHOWING COMPARISON OF PAIN DURATION 
BETWEEN HIORA GROUP AND TRIAMCINOLONE ACETONIDE GROUP 
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DISCUSSION 
Recurrent aphthous stomatitis is one of the common diseases of the oral cavity 
that we confront in our daily practice. This painful ulcerative condition restricts the 
normal activities like eating, swallowing and sometimes speech too becomes difficult. 
17
 Hence the management of this condition is considered to be important and the main 
aim of the treatment includes decreasing the symptoms and reducing the number and 
size of the ulcers. 
1
 
The presently available treatment approaches for RAS has many adverse 
effects which cannot be endured by the patients themselves. Hence a novel treatment 
approach is required to fulfill the management goals for this condition.
1
 Thus we have 
compared HiOra SG gel which is a polyherbal formulation with Triamcinolone 
acetonide (0.1%) gel in the management of RAS in this study. 
  HiOra SG gel is a poly herbal formulation which includes Jasminum 
grandiflorum, Glycyrrhiza glabra, Triphala, Boerrhaavia diffusa, Syzygium 
aromaticum, Ocimum basilicum and Azadirachta indica.  
An invitro study was done by Umamaheswari et al using the extracts of 
Jasminum grandiflorum or Jati and described that it has antiulcer and antioxidant 
properties. 
58
  Licorice root or Glycyrrhiza glabra is considered as one of the ancient 
herbal medicine dating back to 500 BC. Bismelah et al in 2016 discussed about the 
anti inflammatory, anti bacterial and antifungal effects of licorice in his review article. 
59
  According to Yadav et al (2016) Triphala has antibacterial and wound healing 
activity in incision wound. 
60
 In 2008 Sahu et al did a review on Boerrhaavia diffusa 
and discussed about its immunomodulatory potential, antioxidant activity and 
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analgesic effects. 
61
 All these properties are essential in treating RAS. Clove or 
Syzygium aromaticum is another traditional medicine which is being used as early as 
240 BC in Asian countries. It has analgesic and mild anesthetic effects that act on the 
sensory nerve endings and thereby controlling the pain caused due to the ulcers. Also 
it has antimicrobial effects as well. 
62
 In 2012 Khair Ul Bariyah  et al reviewed on the 
phytochemical and pharmacological properties of Ocimum basilicum which is also 
known as Sweet Basil. He described about antimicrobial, immunomodulatory, 
antioxidant, anti-inflammatory and anti toxic activities of Sweet Basil. 
63
 Azadirachta 
indica, commonly known as Neem is another plant with many medicinal uses. This 
medicinal plant has immunomodulatory, antioxidant, antimicrobial, anti ulcer and 
anti-inflammatory properties. 
59
 Thus HiOra SG gel contains various herbal medicines 
that have a combined anti-inflammatory, anti ulcer, antimicrobial, immunomodulatory 
and analgesic actions which can be used effectively in the management of recurrent 
oral ulcers. 
According to Tappuni et al, the ulcer severity was estimated by considering 
six ulcer characteristics like number, site, size, duration, ulcer-free period and pain. 
The total ulcer severity score was calculated which indicated the disease severity. 
64
 In 
our study the ulcer severity was calculated using four ulcer characteristics which 
include number, site, size and pain intensity. The pain duration was also calculated 
after using both the topical medications. 
Patil et al did a study to find the prevalence of recurrent oral ulcers in Indian 
population and he found that more number of patients affected with RAS were seen 
among 31-40 years of age group followed by 21-30 years of age group. 
17
 In the 
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present study, higher number of patients with RAS was seen between 21-30 years of 
age in both the study groups. 
According to Preethi et al the mean pain score in HiOra SG gel group 
was7.67±0.90 on day 0, followed by 4.87±0.99 on day 4 and 1.67±0.73 on day 7. 
Thus the results showed a significant reduction in the pain intensity during follow up 
period after using HiOra gel. 
9
  These results were in accordance with our study. 
Sukumaran et al also did a study to evaluate the clinical efficacy of HiOra SG 
gel in the management of aphthous stomatitis. 
1
 The mean pain score reduced from 
first week to third week and showed a significant reduction of pain intensity which 
was similar to the present research. In our study there was reduction in the mean pain 
score in HiOra SG gel group which was 6.63±1.752 on day 1 followed by 2.77±1.977 
on day 5 and 0.57±1.04 on day 10. The mean pain intensity scores of Triamcinolone 
acetonide group was 6.6±1.993 on day 1, 2.7±1.643 on day 5 and 0.37±0.928 on day 
10 respectively. Thus there was significant reduction in mean pain intensity scores in 
both HiOra SG gel group as well as Triamcinolone acetonide group with a p value 
<0.001.  
In the study done by Preethi et al, the pain intensity showed statistically 
significant reduction in the HiOra gel group on second visit when compared to 5% 
Amlexanox group. 
9
 This result was in contrast to our present research.  
On comparing with placebo, HiOra gel group had a significant decrease in 
pain intensity on the first, second and third visits with p value <0.001 in the study 
done by Sukumaran et al. 
1
 The above mentioned results were also in contrast to our 
study. In this study comparison of the pain intensity scores between HiOra gel group 
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and Triamcinolone acetonide group showed p values 0.945, 0.888 and 0.435 on day 1, 
day 5 and day 10 respectively. Thus in the present study, we can conclude that there 
was no significant association between the two groups in reducing the pain intensity.  
Tappuni et al did the clinical assessment of RAS by calculating the Ulcer 
Severity Score which decreased significantly after topical corticosteroid treatment 
from 34.6 ±7.1 to 27.4± 11 with a P value < 0.001. 
64
 In the present study, the Total 
USS on day 1, day 5 and day 10 were 16.43±11.8555, 9.23±9.946 and 2.43±3.342 
respectively in HiOra gel group. The total USS in triamcinolone acetonide group also 
reduced from 13.97±5.249 to 1.97±4.013 on day 10. Thus the Ulcer severity scores in 
both the groups had a statistically significant difference with a p value <0.001. These 
results were similar to the present study. 
While comparing the total Ulcer severity scores between HiOra gel group and 
Triamcinolone acetonide group, no statistically significant change was detected as the 
p values on day1, day 5 and day 10 were 0.302, 0.274 and 0.628 respectively.  
In the study done by Preethi et al, on first and second follow up visits, there 
was no statistically significant reduction in the number of ulcers between HiOra gel 
group and Amlexanox group. Also there was a statistically significant reduction in the 
mean size of ulcers in Amlexanox group when compared to HiOra gel group. 
9
 
 Sukumaran et al evaluated the reduction in the number of mouth ulcers and 
compared between HiOra gel group and placebo and concluded that there was a 
significant reduction in the mouth ulcers in HiOra gel group. 
1
 
In studies done by Preethi et al and Sukumaran et al, the mean number of 
ulcer, size of the ulcer and pain intensity were analyzed separately where as in our 
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research all the above said ulcer characteristics along with site of the ulcer were 
considered together as Ulcer Severity Score. Based on the previous literature search, 
no other studies have considered Ulcer Severity Score for assessing the severity of the 
disease condition after the treatment with HiOra gel. This has been done in the present 
research. 
In a randomized controlled study done by Mojabi et al therapeutic efficacy of 
ibuprofen was compared with Diphenhydramine where the pain duration was 
compared between the two groups. The comparison between the two groups was not 
statistically significant with a p value 0.57. These findings were consistent with the 
present study. 
42
 The pain duration was evaluated in the present study after the 
intervention with HiOra SG gel and Triamcinolone acetonide gel. The mean pain 
duration in HiOra gel group on the first follow up visit was 4.33±0.844 which reduced 
to 1.57±1.654 on second follow up visit. Thus there was a significant improvement in 
the pain duration after using HiOra SG gel with a p value <0.001. Similarly, in 
Triamcinolone acetonide group the mean pain duration decreased from 4.2±0.997 on 
day 5 to 1.34±1.696 on day 10. Hence there was a statistically significant reduction of 
the mean pain duration in Group II as well with a p value <0.001. While comparing 
the pain duration on day 5 and day 10 between HiOra gel group and Triamcinolone 
acetonide group, the results showed no significant difference with p value 0.578 and 
0.539 on day 5 and day 10 respectively. With this it can be concluded that, the 
reduction in pain duration of RAS was similar in both the groups. 
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In 2013 Deshmukh and Bagewadi et al did a similar study to assess and 
compare the effectiveness of curcumin with Triamcinolone acetonide in the gel form 
in treatment of minor RAS for a period of 7 days. The results showed significant 
reduction in the number, size, pain intensity and duration in both the groups. But there 
was no statistically significant difference on comparing both the groups in the 
treatment of RAS. This study concluded that curcumin can be used as an effective 
alternative medicine to topical steroids in the management of RAS. 
65
 These results 
were identical to the present research. 
Unur et al did a comparative study in 2014 to determine and compare the 
efficacy of a new medicinal plant extract and Triamcinolone acetonide in the 
management of RAS. The extracts of medicinal plants used in the study were Thymus 
vulgaris, Glycyrrhiza glabra, Vitis vinifera, Alpinia officinarum and Urtica dioica. 
There was no significant difference noted between the two groups on comparing the 
mean ulcer size, Effectiveness index and pain scores on day 3 and day 7. Thus the 
study showed similar results to our study. 
66
 
Thus the present study showed that HiOra SG gel which is a poly herbal 
formulation can be used effectively in the management of recurrent oral ulcers. Hence 
the side effects of currently available medications like topical corticosteroids can be 
avoided. Similar study with increased sample size can be done to validate the efficacy 
of HiOra SG gel.  
The Ulcer Severity Score which is being used in the present study can also be 
assimilated in our routine dental practice for the assessment of disease severity and 
also to prove the efficacy of various drugs in the management of recurrent aphthous 
stomatitis. 
SUMMARY &  CONCLUSION
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SUMMARY 
A study titled “Comparison of effectiveness of HiOra SG gel with 
Triamcinolone acetonide gel in Recurrent Aphthous Stomatitis: A Randomized 
Double Blind Controlled Clinical Trial” was conducted in the Department of Oral 
Medicine and Radiology at Vivekanandha dental college for Women between 2016 
and 2018. The study was approved by the institutional ethical committee. 
 It was a comparative study to determine the efficacy of HiOra SG gel with 
Triamcinolone acetonide gel in recurrent aphthous stomatitis patients. The study 
consisted of two groups with 30 subjects in each group. Group I was recurrent 
aphthous stomatitis patients treated with HiOra SG gel and Group II was recurrent 
aphthous stomatitis patients treated with 0.1 % Triamcinolone acetonide ointment 
(Oraways). HiOra SG gel is a poly herbal formulation which is compared with 
triamcinolone acetonide gel in the present study. 
 Each subjects included in both the group were assessed on 5
th
 and 10
th
 day and 
was compared with the baseline data. To compare the efficacy of the drugs Ulcer 
Severity scores were measured and calculated. 
 The following inferences were made in the present study: 
 The age distribution of this study showed increased frequency of patients with 
recurrent aphthous stomatitis within the age range of 21- 30 years in both the 
groups.  ( p value > 0.05) 
 The gender distribution showed more number of females with recurrent 
aphthous stomatitis in both the study groups and thus distribution of aphthous 
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ulcer among males and females were not statistically significant. (p value > 
0.05) 
 A statistically significant reduction in the mean pain intensity scores were seen 
in Group I with p value < 0.001 
 The mean pain intensity scores showed a statistically significant reduction in 
Group II ( p value < 0.001) 
 The total Ulcer Severity Scores in Group I  and Group II showed a statistically 
significant reduction on day 5 and day 10 when compared to day 1 with p 
value < 0.001  
 On comparing the mean pain intensity scores between both the study groups 
on day 1, day 5 and day 10; there was no significant difference between the 
two groups in alleviating the pain caused by RAS ( p values 0.945, 0.888 and 
0.435 respectively) 
 The comparison of Total Ulcer Severity Scores between both the study groups 
on day 1, day 5 and day 10 showed no significant difference between the two 
groups after the treatment ( p values 0.302, 0.274 and 0.628 respectively) 
The results of the present study validate the efficacy of HiOra SG gel in the 
management of recurrent aphthous stomatitis when compared to Triamcinolone 
acetonide gel (0.1%). Hence it can be used as a safer topical medication in treating 
this disease condition.  
In future researches, with increased sample size and using the Ulcer Severity 
Score taken in the study, the effectiveness of HiOra SG gel can be established.  
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CONCLUSION 
This study was done to assess and compare the effectiveness of HiOra SG gel 
with Triamcinolone acetonide gel in the treatment of Recurrent Aphthous Stomatitis.  
The results suggest that there was no significant difference between HiOra SG 
gel and Triamcinolone acetonide gel in reducing the ulcer severity, pain duration and 
pain intensity. No adverse effects were reported by any of the patients after using 
HiOra SG gel in this study. Hence the results of the present research show that this 
polyherbal formulation can be used as a safer and effective alternative medication to 
topical corticosteroids, which is being used as an extensive medication for the 
management of this condition.  
As there are only very few studies to validate the efficacy of herbal medicines 
in managing recurrent oral ulcers, we need more researches with increased sample 
size to substantiate its effects. 
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ANNEXURE 
PATIENT INFORMATION SHEET 
SUBJECT: COMPARISON OF EFFECTIVENESS OF  HIORA SG GEL WITH 
TRIAMCINOLONE ACETONIDE GEL IN RECURRENT APHTHOUS 
STOMATITIS: A RANDOMIZED DOUBLE BLIND CONTROLLED CLINICAL 
TRIAL 
INTRODUCTION: 
          A research is being conducted in Vivekanandha Dental College for Women, 
Tiruchengode, for evaluating the efficacy of HiOra SG gel. Please read this patient 
information sheet thoroughly and ask the researcher any queries you may have about 
the study before signing the consent form. 
EXPLANATION OF PROCEDURES:  
          This study is aimed to evaluate and compare the efficacy of HiOra SG gel in 
recurrent aphthous stomatitis with triamcinolone acetonide gel. The HiOra SG gel 
does not contain any chemical that can harm you. 
         Your participation will be very valuable in the success of this scientific research 
and will be of great benefit to the society. If you are interested the results of the study 
will be informed. 
NOTIFICATION:  
    The informed consent will be used for the research purpose only. It will not be used 
for any other purpose. You will have no expenditure for participating in the study, 
other than your time. 
INCENTIVES: 
    You will not be given any money or gifts to take part in this research. 
BENEFITS: 
    It is hoped that the information gained from this study may provide a safe 
alternative for aphthous stomatitis. 
CONFIDENTIALITY: 
    The information concerning your participation in the study will be kept confidential 
to the full extent permitted by law and used only for scientific purposes. Your name 
will not be used in any report or released in any way. 
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PATIENT CASE- SHEET PROFORMA 
COMPARISON OF EFFECTIVENESS OF HIORA SG GEL WITH 
TRIAMCINOLONE ACETONIDE GEL IN RECURRENT APHTHOUS 
STOMATITIS: A RANDOMIZED DOUBLE BLIND CONTROLLED 
CLINICAL TRIAL 
 
Name:                                                                                                          Date :   
Age / sex: 
OP No:  
Address:  
Phone no:  
Occupation: 
Chief complaint:  
 
 
History of present illness: 
 
Past medical history: 
 
Family history: 
 
Skin lesions, if any: 
 
Intra oral examination: 
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Location and number of ulcers: 
LOCATION NO OF ULCERS PRESENT ABSENT 
 Day 1 Day 5 Day 10  
Labial mucosa     
Buccal mucosa     
Buccal sulcus     
Soft palate     
Ventral surface of 
tongue 
    
Floor of mouth     
Hard palate      
Attached gingiva      
Alveolar ridge      
Dorsum of tongue          
Tonsils      
Pillars of fauces      
Uvula      
Oropharynx     
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Location and size of the ulcers: 
LOCATION SIZE OF THE ULCERS (in mm) 
 Day 1 Day 5 Day 10 
Labial mucosa    
Buccal mucosa    
Buccal sulcus    
Soft palate    
Ventral surface of tongue    
Floor of mouth    
Hard palate     
Attached gingiva     
Alveolar ridge     
Dorsum of tongue         
Tonsils     
Pillars of fauces     
Uvula     
Oropharynx    
 
Pain scale: 
0 1 2 3 4 5 6 7 8 9 10 
           
 
Provisional diagnosis: 
Treatment plan: 
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INFORMED CONSENT FORM  
 
STUDY TITLE:  COMPARISON OF EFFECTIVENESS OF HIORA SG 
GELWITH TRIAMCINOLONE ACETONIDE GEL IN RECURRENT APHTHOUS 
STOMATITIS: A RANDOMIZED DOUBLE BLIND CONTROLLED CLINICAL 
TRIAL 
Investigator: Dr. Sudhaa Mani M            Observer: Dr Chitra Mohan                                    
 
Name    : Mr/ Ms:  _______________________                                    Sex: 
male/female                                                                            Age       :           yrs 
Address: _______________________________ 
                _______________________________ 
                _______________________________ 
I__________________________ give my consent voluntarily to participate in this 
study. I agree to the following: 
1. I have been informed to my satisfaction about the purpose of the study and 
study procedure. 
2. I understand that the study involves question which may sometimes be 
personal. 
3. I agree to co –operate fully for complete examination 
4. I am told that the investigating doctor and the institution will keep my 
identity confidential. 
5. I understand that I have rights to withdraw myself from the study and also 
that the investigator the right to exclude me from the research at any point of 
time. 
 
 
 
Name of participant                                                         Signature /thumb impression  
Signature of investigator                                                                      Date:       
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வ       : மரு. சுதா மணி                                    வ    : மரு.              
                         
     :  ஆஃப்ததாஸ் வாய்ப்புண்                          - 
ஒரு மருத்துவ ஆய்வு. 
   
     :   /      _______________________             : 
  /     
வ   :                                                                                  
  வ   : _______________________________ 
                _______________________________ 
                _______________________________ 
                                                                                               
    __________________________________                   
                                வ            
                       .  
1.                             வ   
           .  
2.                                வ       சுயம் 
                           முன்   வ         .  
3.       வ                                  
      .  
4.              வ வ                         வ    
         வ        வ          
              .  
5.                                    
    வ             வ         வ வ             
         வ         .  
 
இட :                           
                                                                                                              கையயாப்பம் 
 
தததி :   
MASTER CHART FOR TRIAMCINOLONE ACETONIDE GEL GROUP 
Sl.No Age/
Sex 
USS 
Day 1 
USS 
Day 5 
USS 
Day 
10 
Pain 
Score 
Day 1 
Pain 
Score 
Day 5 
Pain 
Score 
Day10 
Pain 
Duration 
Score 
Day 5 
Pain 
Duration 
Score Day10 
1 22/F 11 4 0 7 2 0 3 0 
2 23/F 19 9 0 8 4 0 5 3 
3 22/F 18 8 0 8 3 0 5 1 
4 20/F 13 3 0 6 1 0 4 0 
5 22/F 9 0 0 6 0 0 2 0 
6 23/F 12 5 0 9 3 0 5 1 
7 28/F 17 10 0 9 5 0 5 3 
8 21/F 17 5 0 9 1 0 4 0 
9 22/F 19 6 0 9 3 0 4 0 
10 18/F 14 9 5 5 4 2 4 0 
11 20/F 8 3 0 5 1 0 4 0 
12 18/M 33  26 18 7 4 1 5 5 
13 19/F 19 14 8 8 5 2 5 5 
14 56/M 8 3 0 4 1 0 4 0 
15 34/F 15 10 6 7 4 2 5 4 
16 37/M 8 4 0 4 1 0 4 0 
17 25/M 10 7 3 5 3 0 4 1 
18 26/M 12 4 0 5 2 0 3 0 
19 55/M 11 5 0 5 2 0 4 1 
20 36/M 13 7 0 7 4 0 5 1 
21 24/M 12 7 0 7 3 0 5 1 
22 21/M 17 8 4 5 2 0 5 0 
23 20/F 9 4 0 3 1 0 2 0 
24 18/F 14 10 5 3 1 0 2 0 
25 32/F 7 0 0 4 0 0 3 0 
26 25/F 15 7 0 9 4 0 5 2 
27 29/M 11 5 0 8 3 0 5 1 
28 52/F 17 9 0 8 3 0 5 2 
29 28/F 20 13 8 10 7 4 5 5 
30 24/F 11 6 0 8 4 0 5 3 
 
MASTER CHART FOR HIORA SG GEL GROUP 
Sl.No Age/
Sex 
USS 
Day 1 
USS 
Day 5 
USS 
Day 
10 
Pain 
Score 
Day 1 
Pain 
Score 
Day 5 
Pain 
Score 
Day10 
Pain 
Duration 
Score Day5 
Pain 
Duration 
Score 
Day10 
1 31/M 8 3.5 0 6 2 1 5 1 
2 28/F 8 0 0 6 0 0 3 0 
3 22/F 11 6 0 8 4 0 5 2 
4 21/F 12 7 0 7 3 0 5 1 
5 22/F 21 12 2.5 8 4 0 4 2 
6 22/F 33 13 3.5 6 3 1 5 4 
7 32/F 6 2.5 0 4 1 0 4 2 
8 21/F 11 6 2 5 2 0 4 1 
9 28/F 9 0 0 5 0 0 3 0 
10 22/F 10 3.5 0 7 1 0 5 0 
11 25/F 10 3 1.5 6 0 0 4 0 
12 19/F 10 4 1.5 4 1 0 4 0 
13 22/F 11 8 2 5 2 0 5 1 
14 19/F 27 13 5 8 3 0 5 2 
15 22/F 14 4 0 5 1 0 3 0 
16 20/F 16 11 0 8 5 0 5 0 
17 22/F 8 0 0 6 0 0 2 0 
18 36/M 19 12 5 8 4 1 5 4 
19 19/F 68 54.5 2.5 8 4 2 5 5 
20 50/F 16 11 8 9 5 3 5 3 
21 50/F 7 3 0 5 1 0 3 0 
22 40/M 19 14 10 8 5 3 4 4 
23 36/F 14 11 1.5 7 5 0 5 2 
24 31/F 10 4.5 0 5 1 0 4 0 
25 20/F 9 3 0 5 1 0 4 0 
26 33/F 27 16 7 9 5 2 5 1 
27 32/F 16 9 0 6 3 0 4 1 
28 26/M 24 18 10 8 5 2 5 5 
29 25/F 19 9.5 0 10 5 0 5 2 
30 34/M 20 15 9 9 7 3 5 4 
 
